Core Insights - The report emphasizes the construction of a strategy portfolio based on industry and thematic ETFs, leveraging insights from previous strategy reports on industry rotation and ETF market overview [2]. Strategy Update - The strategy portfolio includes various ETFs with specific holdings and weightings, such as: - Wine ETF with a market value of 184.16 billion, holding a significant position in the liquor industry (84.84%) [3]. - Real Estate ETF valued at 6.61 billion, fully invested in real estate development (100%) [3]. - Tourism ETF at 88.57 billion, primarily focused on the aviation and airport sector (33.21%) [3]. - New additions include Agriculture and Fishery ETF and Grain ETF, with respective holdings in aquaculture (46.89%) and planting (49.63%) [3]. - The strategy's performance for the period from February 9 to February 13, 2026, showed a cumulative net return of approximately -0.38%, underperforming the CSI 300 ETF by about -0.85% [3]. Performance Tracking - Since October 14, 2024, the strategy has achieved a cumulative return of approximately 37.93%, outperforming the CSI 300 ETF by about 14.43% [3][4]. - The report includes a performance chart illustrating the cumulative return of the industry rotation ETF strategy since its inception [4]. Weekly Holdings and Performance - The report details the weekly performance of various ETFs, indicating that the strategy will continue to hold Wine, Real Estate, Tourism, and Traditional Chinese Medicine ETFs while adding Agriculture and Grain ETFs [11]. - The average return of the ETF portfolio for the week was -0.38%, with a notable underperformance compared to the CSI 300 ETF [11].

Group 1: Report Overview - The report is a weekly strategy report on industry rotation TF from February 2, 2026, to February 8, 2026, released on February 9, 2026 [1][2] - The strategy is based on two previous reports and constructs an ETF - based strategy portfolio [2] Group 2: Investment Recommendations Current Holdings and Changes - ETFs to be continued to hold include Building Materials ETF (159745, market value 21.67 billion yuan), Real Estate ETF (159707, market value 6.40 billion yuan), Petrochemical ETF (159731, market value 17.46 billion yuan), Chemical ETF (159870, market value 340.36 billion yuan), and Rare Metals ETF (562800, market value 62.40 billion yuan) [3] - ETFs to be newly added or adjusted to hold include Tourism ETF (159766, market value 91.07 billion yuan), Wine ETF (512690, market value 192.66 billion yuan), Traditional Chinese Medicine ETF (560080, market value 26.52 billion yuan), New Energy Vehicle ETF (515700, market value 19.75 billion yuan), and Agricultural ETF Harvest (516550, market value 2.03 billion yuan) [3] - ETFs to be removed from the portfolio include Non - Ferrous Metals ETF (512400, market value 352.52 billion yuan), Gold Stocks ETF (517520, market value 151.34 billion yuan), Grain ETF (159698, market value 4.66 billion yuan), Securities and Insurance ETF E Fund (512070, market value 201.73 billion yuan), and Agricultural ETF (159825, market value 26.26 billion yuan) [11] Sector Recommendations - The model recommends allocating to sectors such as cement, real estate development, and airport aviation in the week of February 9, 2026 [12] - In the next week, the strategy will newly hold Game ETF, Wine ETF, Traditional Chinese Medicine ETF, and New Energy Vehicle ETF, and continue to hold Building Materials ETF, Real Estate ETF, and Petrochemical ETF [12] Group 3: Performance Tracking - From February 2 to February 6, 2026, the cumulative net return of the strategy was approximately - 3.85%, and the excess return relative to the CSI 300 ETF was approximately - 2.53% [3] - From October 14, 2024, to February 6, 2026, the out - of - sample cumulative return of the strategy was approximately 38.45%, and the cumulative excess return relative to the CSI 300 ETF was approximately 15.41% [3]

Group 1 - The Chinese medicine sector experienced a short-term surge, with Hansen Pharmaceutical achieving two consecutive trading limits, and companies such as Guhang Medicine, China Resources Sanjiu, Guangdong Wannianqing, Biotech Valley, and Dong'e Ejiao also seeing gains [1] - The Chinese Medicine ETF (560080) recorded a transaction volume of 78.1084 million yuan [1] - The recent rise in the sector was influenced by the "Implementation Plan for the High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)" [1]

Group 1 - The core viewpoint of the news is the collective rise of traditional Chinese medicine (TCM) stocks following the release of the "Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)" by eight departments including the Ministry of Industry and Information Technology on February 5, 2026 [1] - The plan outlines six key tasks: improving raw material quality and supply stability, collaborative innovation, enhancing manufacturing capabilities, revitalizing the national medicine industry, and cultivating outstanding enterprises [1] - By 2030, the goal is to promote a number of innovative TCM drugs to be approved for market launch and to cultivate ten major varieties of traditional Chinese medicine [1] Group 2 - The upcoming release of the new essential drug catalog in 2026 is expected to include approximately 40% traditional Chinese medicine products, which will serve as a core policy driver for the growth of innovative TCM drugs [1] - The market is witnessing a resurgence of old TCM brands while new brands are gradually emerging, supported by the cleaning up of TCM licenses and resource allocation towards established brands [1] - As of February 6, 2026, the CSI Traditional Chinese Medicine Index (930641) rose by 2.45%, with significant increases in stocks such as Panlong Pharmaceutical (up 10.01%) and Longshen Rongfa (up 9.99%) [1] Group 3 - The CSI Traditional Chinese Medicine Index closely tracks the performance of listed companies involved in the production and sales of TCM [2] - As of January 30, 2026, the top ten weighted stocks in the CSI Traditional Chinese Medicine Index accounted for 55.13% of the index, including companies like Yunnan Baiyao and Tongrentang [2]

Core Insights - The report highlights a record level of activity in the Hong Kong and Shanghai Stock Connect ETF market in 2025, with a net buy of 14,048 billion HKD, a year-on-year increase of approximately 74% [1] - The communication and non-ferrous metal sectors emerged as the leading gainers, with the communication ETF (515880.SH) achieving an annual growth of 118.91% [1] - The market showed a cautious and rational funding allocation preference, focusing on low-volatility and high-liquidity assets [2] Market Activity - The annual net inflow for the Stock Connect market reached 14,048 billion HKD, with September alone contributing a record net inflow of 1,885 billion HKD [1] - The average daily trading volume for the Hong Kong Stock Connect was 1,259 billion HKD, a year-on-year increase of 229%, while the Shanghai and Shenzhen Stock Connect saw an average daily trading volume of 2,064 billion RMB, up 67% [1] Sector Performance - The communication sector and non-ferrous metals were the standout performers, with several ETFs in these categories seeing gains exceeding 89% [1] - In contrast, consumer and traditional Chinese medicine ETFs underperformed, with the liquor ETF (512690.SH) declining by 13.13% and the Chinese medicine ETF experiencing a drop to -5.77% due to policy impacts [1] Fund Allocation Trends - The market showed a preference for stable assets, with significant inflows into the securities ETF (512880.SH) and the CSI 300 ETF (510330.SH), each attracting nearly 30 billion RMB [2] - The technology sector ETFs, such as the Sci-Tech 50 ETF (588000.SH), faced substantial outflows, with over 42.3 billion RMB leaving these funds [2] Institutional Performance - Smaller fund companies demonstrated notable performance through high-elasticity products, with Huafu Fund achieving an average return exceeding 70% due to its AI ETF (515980.SH) [3] - The institutional landscape is characterized by a "stronger getting stronger" dynamic, with leading firms like Huaxia Fund and E Fund seeing significant growth, while smaller firms focus on niche market opportunities [3] Future Outlook - The report anticipates that competition among institutions will increasingly focus on innovation in niche categories and service enhancement, with a need for smaller funds to identify differentiated opportunities in specialized ETFs and cross-border products [3]

Group 1 - The core viewpoint of the news highlights the performance of the Traditional Chinese Medicine (TCM) sector, with the Zhongzheng TCM Index experiencing a slight decline of 0.28% as of December 8, 2025, while individual stocks showed mixed results, with Kangyuan Pharmaceutical leading with a gain of 1.71% [1] - The recent release of the new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the first Commercial Health Insurance Innovative Drug Catalog (2025), marks the 8th adjustment since the establishment of the National Medical Insurance Bureau, adding 114 new drugs, including 6 TCM products [1] - The Zhongzheng TCM Index includes companies involved in TCM production and sales, reflecting the overall performance of TCM-related listed companies [2] Group 2 - Huafu Securities recommends focusing on innovative drugs, particularly those with revenue and commercialization capabilities, as well as exploring potential big business development opportunities in the biotech and pharmaceutical sectors [2] - The medical device sector is expected to experience a policy turning point, with stock prices, valuations, and configurations at a low point, indicating a potential fundamental turnaround [2] - The TCM ETF closely tracks the Zhongzheng TCM Index, with the top ten weighted stocks accounting for 54.79% of the index, including notable companies such as Yunnan Baiyao and Tongrentang [2]

Market Overview - The market experienced a decline with all three major indices closing lower: Shanghai Composite Index down 0.51%, Shenzhen Component Index down 0.78%, and ChiNext Index down 1.12% [1] Sector Performance - Coal, wind power equipment, and traditional Chinese medicine sectors showed strong gains, while energy metals, internet services, and software development sectors faced significant declines [1] - Main capital inflows were observed in small metals, optical electronics, and non-ferrous metals industries [1] ETF Performance - Related ETFs such as those in non-ferrous metals, electricity, and traditional Chinese medicine performed well, likely influenced by relevant news [1] Federal Reserve Insights - China Galaxy Securities noted that market expectations for a Federal Reserve rate cut in December have exceeded 80%, leading to a rebound in gold prices and a new high for silver prices [1] - The ongoing rate cut cycle and potential shift from balance sheet reduction to expansion may continue to support rising prices for gold and silver [1] Resource Sector Outlook - CITIC Construction indicated that conditions are accumulating for a strong performance in resource products, which may become a new main investment theme in A-shares following technology [1] - The competition for key resources amid external geopolitical tensions is expected to be a significant factor driving the strength of resource products [1] New Energy and Grid Investment - Zhongyou Securities highlighted that the demand for new energy consumption is surging under the "dual carbon" goals, leading to a rapid growth cycle in grid investment [2] - The urgency for smart grid upgrades, along with infrastructure needs for ultra-high voltage channels and distribution network improvements, is driving this investment trend [2] Traditional Chinese Medicine Pricing Regulation - The launch of the drug price registration system in China is part of a broader initiative to regulate the prices of traditional Chinese medicine [3] - Multiple regions, including Heilongjiang, Anhui, and others, are actively implementing price governance measures targeting high-priced traditional Chinese medicines [3] - The goal is to establish a unified, open, and competitively ordered drug market across the country [3]

Core Viewpoint - The A-share market continues to decline, with major indices experiencing losses, while the traditional Chinese medicine (TCM) ETFs show resilience and growth amid a recovering market sentiment in the TCM sector [1][2]. Market Performance - The Shanghai Composite Index fell by 0.51% to 3878 points, the Shenzhen Component Index dropped by 0.78%, and the ChiNext Index decreased by 1.12% [1]. - The total market turnover reached 1.68 trillion yuan, an increase of 763 billion yuan compared to the previous trading day, with over 3800 stocks declining [1]. TCM ETFs - TCM ETFs, including the TCM ETF, TCM ETF Huatai-PB, and TCM 50 ETF, experienced gains, with respective increases of 0.92%, 0.90%, and 0.81% [2]. - The TCM ETF tracks the CSI Traditional Chinese Medicine Index, with key stocks including Yunnan Baiyao, Pien Tze Huang, and Tong Ren Tang [1][2]. TCM Market Trends - The TCM market is showing signs of recovery, with increased market activity and positive investment sentiment [2]. - The TCM sector benefits from both pharmaceutical and consumer attributes, with a high dividend yield of 2.69% over the past 12 months, placing it in the 90.91% historical percentile since its inception [2]. Price Governance in TCM - Multiple regions in China have initiated price governance for traditional Chinese medicine, aiming to create a unified and competitive drug market [3][4]. - The focus is on high-priced TCM products with significant clinical usage, particularly those sold primarily in the outpatient market [4]. Industry Dynamics - The ongoing price governance and centralized procurement are expected to lead to price convergence between hospital and outpatient markets, reshaping competitive factors in the industry [4]. - Companies with unique products, strong clinical value, and effective cost control are likely to gain competitive advantages [4]. Investment Themes - Three main investment themes are identified: 1. Price governance, focusing on price reductions and market share for competitive products [5]. 2. Consumption recovery, driven by macroeconomic improvement and aging population, benefiting TCM sales [6]. 3. State-owned enterprise reform, which is expected to enhance performance and create investment opportunities [6]. Recommended Investment Targets - Companies with strong R&D capabilities, unique products, and those less affected by centralized procurement are recommended for investment [6]. - Emphasis is placed on TCM brands with strong market presence and those benefiting from state-owned enterprise reforms [6].

Group 1 - The Zhongzheng Traditional Chinese Medicine Index (930641) increased by 0.32%, with notable gains from companies such as Guangdong Wannianqing (301111) up 12.03%, and Panlong Pharmaceutical (002864) up 5.35% [1] - The demand for new therapies such as peptides, ADCs, small nucleic acids, and CGT is expected to remain high, with a recovery in outsourcing demand anticipated due to the overseas interest rate cut cycle [1] - The adjustment of the basic drug catalog is expected to continue, presenting opportunities for the adjustment of traditional Chinese medicine varieties [1] Group 2 - The Zhongzheng Traditional Chinese Medicine Index includes companies involved in the production and sales of traditional Chinese medicine, reflecting the overall performance of the sector [2] - As of November 28, 2025, the top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index accounted for 54.79% of the index, with notable companies including Yunnan Baiyao (000538) and Pianzaihuang (600436) [2]

Group 1 - The core viewpoint of the articles highlights the positive performance of the Traditional Chinese Medicine (TCM) sector, with the Zhongzheng TCM Index rising by 0.79% and specific stocks like Guangdong Wannianqing and Tailong Pharmaceutical showing significant gains [1] - The TCM sector is characterized as a defensive segment with both pharmaceutical and consumer attributes, showcasing a dividend advantage with the TCM ETF's 12-month dividend yield reaching 2.87% [1] - The peak flu season has arrived, with the H3N2 strain prevalent in Beijing, presenting opportunities for the TCM sector [1] Group 2 - The adjustment of the basic drug catalog is expected to continue, with a focus on opportunities for increasing TCM varieties [1] - The trend of declining prices for TCM materials is anticipated to lead to a recovery in gross margins, with optimism regarding the clearance of social inventories and innovation-driven growth [1] - The top ten weighted stocks in the Zhongzheng TCM Index account for 54.79% of the index, including major companies like Yunnan Baiyao and Tongrentang [2]